Homology models of dipeptidyl peptidases 8 and 9 with a focus on loop predictions near the active site

Proteins: Structure, Function and Genetics

Volumn 66, Issue 1, 2007, Pages 160-171

  Rummey, Christian ^a   Metz, Günther ^a  

^a Santhera Pharmaceuticals   (Switzerland)

Author keywords

Diabetes; DP4; DP8; DP9; Homology modeling; Inhibitor selectivity; Loop refinement

Indexed keywords

CELL PROTEIN; DIPEPTIDYL PEPTIDASE; DIPEPTIDYL PEPTIDASE 8; DIPEPTIDYL PEPTIDASE 9; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FIBROBLAST ACTIVATION PROTEIN; HYDROLASE; NVP 728; SITAGLIPTIN; VILDAGLIPTIN;

ARTICLE; BETA CHAIN; DRUG DESIGN; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME CONFORMATION; ENZYME SPECIFICITY; ENZYME STRUCTURE; HUMAN; MOLECULAR MODEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; SEQUENCE ALIGNMENT;

ADENOSINE DEAMINASE; AMINO ACID SEQUENCE; ANTIGENS, CD26; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DIPEPTIDASES; DIPEPTIDYL PEPTIDASES; GLYCOPROTEINS; HUMANS; HYDROLASES; LIGANDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; SEQUENCE ALIGNMENT; STRUCTURAL HOMOLOGY, PROTEIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33845648469     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.21138     Document Type: Article

References (47)

1. Demuth HU, McIntosh CH, Pederson RA. Type 2 diabetes-therapy with dipeptidyl peptidase IV inhibitors. Biochim Biophys Acta 2005;1751:33-44.
2. Gorrell MD. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci 2005;108:277-292.
3. Sinclair EM, Drucker DJ. Glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase IV inhibitors: new therapeutic agents for the treatment of type 2 diabetes. Curr Opin Endocrinol Diabetes 2005;12:146-151.
4. Ajami K, Abbott CA, Obradovic M, Gysbers V, Kahne T, McCaughan GW, Gorrell MD. Structural requirements for catalysis, expression, and dimerization in the CD26/DPIV gene family. Biochemistry 2003;42:694-701.
5. Abbott CA, McCaughan GW, Levy MT, Church WB, Gorrell MD. Binding to human dipeptidyl peptidase IV by adenosine deaminase and antibodies that inhibit ligand binding involves overlapping, discontinuous sites on a predicted beta propeller domain. Eur J Biochem 1999;266:798-810.
6. Rosenblum JS, Kozarich JW. Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. Curr Opin Chem Biol 2003;7:496-504.
7. Rasmussen HB, Branner S, Wiberg FC, Wagtmann N. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat Struct Biol 2003;10:19-25.
8. Aertgeerts K, Levin I, Shi L, Snell GP, Jennings A, Prasad GS, Zhang Y, Kraus ML, Salakian S, Sridhar V, Wijnands R, Tennant MG. Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha. J Biol Chem 2005; 280:19441-19444.
9. Strop P, Bankovich AJ, Hansen KC, Garcia KC, Brunger AT. Structure of a human A-type potassium channel interacting protein DPPX, a member of the dipeptidyl aminopeptidase family. J Mol Biol 2004;343:1055-1065.
10. Fulop V, Bocskei Z, Polgar L. Prolyl oligopeptidase: an unusual beta-propeller domain regulates proteolysis. Cell 1998;94:161-170.
11. Augustyns K, Van der Veken P, Haemers A. Inhibitors of proline-specific dipeptidyl peptidases: DPP-IV inhibitors as a novel approach for the treatment of Type 2 diabetes. Expert Opin Ther Patents 2005;15:1387-1407.
12. Holst JJ. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors. Expert Opin Emerg Drugs 2004;9:155-166.
13. Weber AE. Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J Med Chem 2004;47:4135-4141.
14. Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005;7:692-698.
15. Villhauer EB, Brinkman JA, Naderi GB, Burkey BF, Dunning BE, Prasad K, Mangold BL, Russell ME, Hughes TE. 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2- cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003;46:2774-2789.
16. Villhauer EB, Brinkman JA, Naderi GB, Dunning BE, Mangold BL, Mone MD, Russell ME, Weldon SC, Hughes TE. 1-[2-[(5-Cyanopyridin-2-yl)amino]ethylamino] acetyl-2-(S)-pyrrolidinecarbon itrile: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2002;45:2362-2365.
17. Oefner C, D'Arcy A, Mac SA, Pierau S, Gardiner R, Dale GE. High-resolution structure of human apo dipeptidyl peptidase IV/ CD26 and its complex with 1-[([2-[(5-iodopyridin-2-yl)amino]-ethyl]amino)-acetyl]-2-cyano-(S) -pyrrol idine. Acta Crystallogr D Biol Crystallogr 2003;59:1206-1212.
18. Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, Hickey GJ, Kowalchick JE, Leiting B, Lyons K, Marsilio F, McCann ME, Patel RA, Petrov A, Scapin G, Patel SB, Roy RS, Wu JK, Wyvratt MJ, Zhang BB, Zhu L, Thornberry NA, Weber AE. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a] pyrazin-7(8H)-yl]-1-(2,4,5-trifluoropnenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005;48:141-151.
19. Lankas GR, Leiting B, Roy RS, Eiermann GJ, Beconi MG, Biftu T, Chan CC, Edmondson S, Feeney WP, He H, Ippolito DE, Kim D, Lyons KA, Ok HO, Patel RA, Petrov AN, Pryor KA, Qian X, Reigle L, Woods A, Wu JK, Zaller D, Zhang X, Zhu L, Weber AE, Thornberry NA. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005;54:2988-2994.
20. Lankas GR, Leiting B, Sinha RS, Eiermann GJ, Biftu T, Kim D, Ok H, Weber AE, Thornberry NA. Inhibition of DPP8/9; Results in toxicity in preclinical species: potential importance of selective dipeptidyl peptidase IV inhibition for treatment of type 2 DM, Presented at the American Diabetes Association 64th Scientific Session, Orlando, FL, June 4-8, 2004 (Abstract 7-OR).
21. Jacobson MP, Sali A. Comparative protein structure modeling and its applications to drug discovery. Ann Rep Med Chem 2004;39:259-276.
22. Fiser A. Protein structure modeling in the proteomics era. Expert Rev Proteomics 2004;1:97-110.
23. Kopp J, Schwede T. Automated protein structure homology modeling: a progress report. Pharmacogenomics 2004;5:405-416.
24. Hillisch A, Pineda LF, Hilgenfeld R. Utility of homology models in the drug discovery process. Drug Discov Today 2004;9: 659-669.
25. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994;22:4673-4680.
26. Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser 1999;41:95-98.
27. Prime 1.2, Schrödinger, LLC, Portland, OR.
28. Jacobson MP, Pincus DL, Rapp CS, Day TJ, Honig B, Shaw DE, Friesner RA. A hierarchical approach to all-atom protein loop prediction. Proteins 2004;55:351-367.
29. Rapp CS, Friesner RA. Prediction of loop geometries using a generalized born model of solvation effects. Proteins 1999;35:173-183.
30. DeLano WL. The PyMOL Molecular Graphics System, version 0.98. DeLano Scientific, San Carlos, CA, US. Available on http://www.pymol.org
31. Hiramatsu H, Kyono K, Higashiyama Y, Fukushima C, Shima H, Sugiyama S, Inaka K, Yamamoto A, Shimizu R. The structure and function of human dipeptidyl peptidase IV, possessing a unique eight-bladed β-propeller fold. Biochem Biophys Res Commun 2003;302:849-854.
32. Aertgeerts K, Ye S, Tennant MG, Kraus ML, Rogers J, Sang BC, Skene RJ, Webb DR, Prasad GS. Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation. Protein Sci 2004;13:412-421.
33. Nordhoff S, Cerezo-Gálvez S, Feurer A, Hill O, Matassa VG, Metz G, Rummey C, Thiemann M, Edwards PJ. The reversed binding of b-phenethylamine inhibitors of DPP-IV. X-ray structures and properties of novel fragment and elaborated inhibitors. Bioorg Med Chem Lett 2006;16:1744-1748.
34. Bjelke JR, Christensen J, Branner S, Wagtmann N, Olsen C, Kanstrup AB, Rasmussen HB. Tyrosine 547 constitutes an essential part of the catalytic mechanism of dipeptidyl peptidase TV. J Biol Chem 2004;279:34691-34697.
35. Peters JU, Weber S, Kritter S, Weiss P, Wallier A, Boehringer M, Hennig M, Kuhn B, Loeffler BM. Aminomethylpyrimidines as novel DPP-IV inhibitors: a 10(5)-fold activity increase by optimization of aromatic substituents. Bioorg Med Chem Lett 2004;14:1491-1493.
36. Thoma R, Loffler B, Stihle M, Huber W, Ruf A, Hennig M. Structural basis of proline-specific exopeptidase activity as observed in human dipeptidyl peptidase-IV. Structure 2003;11: 947-959.
37. Engel M, Hoffmann T, Wagner L, Wermann M, Heiser U, Kiefersauer R, Huber R, Bode W, Demuth HU, Brandstetter H. The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism. Proc Natl Acad Sci USA 2003;100:5063-5068.
38. Weihofen WA, Liu J, Reutter W, Saenger W, Fan H. Crystal structure of CD26/dipeptidyl-peptidase IV in complex with adenosine deaminase reveals a highly amphiphilic interface. J Biol Chem 2004;279:43330-43335.
39. Abbott CA, Yu DM, Woollatt E, Sutherland GR, McCaughan GW, Gorrell MD. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur J Biochem 2000;267:6140-6150.
40. Brandt W. Development of a tertiary-structure model of the C-terminal domain of DPP IV. Adv Exp Med Biol 2000;477:97-101.
41. http://www.ncbi.nlm.nih.gov/BLAST/
42. Ajami K, Abbott CA, McCaughan GW, Gorrell MD. Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity. Biochim Biophys Acta 2004;1679:18-28.
43. Hiramatsu H, Yamamoto A, Kyono K, Higashiyama Y, Fukushima C, Shima H, Sugiyama S, Inaka K, Shimizu R. The crystal structure of human dipeptidyl peptidase IV (DPPIV) complex with diprotin A. Biol Chem 2004;385:561-564.
44. Sherman W, Day T, Jacobson MP, Friesner RA, Farid R. Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem 2006;49:534-553.
45. Evers A, Gohlke H, Klebe G. Ligand-supported homology modelling of protein binding-sites using knowledge-based potentials. J Mol Biol 2003;334:327-345.
46. Lu IL, Lee SJ, Tsu H, Wu SY, Kao KH, Chien CH, Chang YY, Chen YS, Cheng JH, Chang CN, Chen TW, Chang SP, Chen X, Jiaang WT. Glutamic acid analogues as potent dipeptidyl peptidase IV and 8 inhibitors. Bioorg Med Chem Lett 2005;15:3271-3275.
47. Rummey C, Nordhoff S, Thiemann M, Metz G. In silico fragment-based discovery of DPP-IV S1 pocket binders. Bioorg Med Chem Lett 2006;16:1405-1409.